Skip to main content

Advertisement

SpringerLink
Log in

Recurrence of giant cell tumour of bone: role of p53, cyclin D1, β-catenin and Ki67

  • Original Paper
  • Published:
International Orthopaedics Aims and scope Submit manuscript

Abstract

Purpose

To determine various clinical, radiographic, and pathological parameters which may indicate an increased risk of Giant cell tumour of bone (GCTB) recurrence after surgical therapy.

Methods

The study included a total of 164 GCTB samples; 118 (72 %) primary tumours, and 46 (28 %) recurrences; which were analyzed on immunohistochemistry for expression of Ki67, p53, cyclin D1, and β-catenin.

Results

Among 13 analyzed clinical, radiological, and histological variables, which presented possible predictive factors for the incidence of GCTB relapse, univariate logistic regression (ULR) extract three highly statistically significant parameters: 1) lesion localization, 2) nuclear p53 expression in mononuclear cells, and 3) nuclear cyclin D1 expression in giant multinuclear cells. The multivariate logistic regression (MLR), revealing that p53 expression in mononuclear cells was the most significant predictive factor (HR = 6,181 p < 0,001), the positivity of which indicated six times higher probability for recurrence in GCTB. The expression of cyclin D1 in giant cells, containing less than 15 nuclei, was also statistically significant (HR = 8,398, p = 0,038) for predicting the recurrence, and demonstrated eight times more frequent recurrence in positive tumours.

Conclusions

This study confirmed independent predicting factors for GCTB reccurence: p53 expression in mononuclear tumour cells and cyclin D1 expression in giant multinuclear cells. Results are new addition to generally known parameters, such as: localization of lesion, number of surgical interventions, clear destruction of cortex with the presence of extracompartmental lesion, and histological criteria for malignancy and can help in further research and treatment of GCTB.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Errani C, Ruggieri P, Asenzio MA (2010) Giant cell tumor of the extremity: a review of 349 cases from a single institution. Cancer Treat Rev 36:1–7

    Article  PubMed  Google Scholar 

  2. Yasko AW (2002) Giant cell tumor of bone. Curr Oncol Rep 4:520–526

    Article  PubMed  Google Scholar 

  3. Domovitov SV, Healey JH (2010) Primary malignant giant-cell tumor of bone has high survival rate. Ann Surg Oncol 17:694–701

    Article  PubMed  Google Scholar 

  4. Mendenhall WM, Zlotecki RA, Scarborough MT, Gibbs CP, Mendenhall NP (2006) Giant cell tumor of bone. Am J Clin Oncol 29:96–99

    Article  PubMed  Google Scholar 

  5. Raskin KA, Schwab JH, Mankin HJ, Springfield DS, Hornicek FJ (2013) Giant cell tumor of bone. J Am Acad Orthop Surg 21:118–126

    Article  PubMed  Google Scholar 

  6. Wulling M, Engels C, Jesse N, Werner M, Delling G, Kaiser E (2001) The nature of giant cell tumor of bone. J Cancer Res Clin Oncol 127:467–474

    Article  CAS  PubMed  Google Scholar 

  7. Balke M, Schremper L, Gebert C et al (2008) Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol 134:969–978

    Article  CAS  PubMed  Google Scholar 

  8. Alberghini M, Kliskey K, Krenacs T et al (2010) Morphological and immunophenotypic features of primary and metastatic giant cell tumour of bone. Virchows Arch 456(1):97–103

    Article  CAS  PubMed  Google Scholar 

  9. Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH (2011) Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Relat Res 469:591–599

    Article  PubMed  Google Scholar 

  10. Blackley HR, Wunder JS, Davis AM, White LM, Kandel R, Bell RS (1999) Treatment of giant-cell tumors of long bones with curettage and bone-grafting. J Bone Joint Surg Am 81:811–820

    Article  CAS  PubMed  Google Scholar 

  11. Zhu Z, Zhang C, Zhao S, Dong Y, Zeng B (2013) Partial wrist arthrodesis versus arthroplasty for distal radius giant cell tumours. Int Orthop 37(11):2217–2311

    Article  PubMed  PubMed Central  Google Scholar 

  12. Turcotte RE, Wunder JS, Isler MH et al (2002) Giant cell tumor of long bone: a Canadian Sarcoma Group study. Clin Orthop Relat Res 397:248–258

    Article  Google Scholar 

  13. Niu X, Zhang Q, Hao L et al (2012) Giant cell tumor of the extremity: retrospective analysis of 621 Chinese patients from one institution. J Bone Joint Surg Am 94:461–467

    Article  PubMed  Google Scholar 

  14. van der Heijden L, Piner SR, van de Sande MA (2016) Pigmented villonodular synovitis: a crowdsourcing study of two hundred and seventy two patients. Int Orthop. doi:10.1007/s00264-016-3208-1

    PubMed  Google Scholar 

  15. Becker WT, Dohle J, Bernd L et al (2008) Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. J Bone Joint Surg Am 90:1060–1067

    Article  PubMed  Google Scholar 

  16. Jiang HL, Jiang LM, Han WD (2015) Wnt/β-catenin signaling pathway in lung cancer stem cells is a potential target for the development of novel anticancer drugs. J BUON 20(4):1094–100

    PubMed  Google Scholar 

  17. Rousseau MA, Luca AH, Lazennec JV (2004) Metachronous multicentric giant cell tumor of the bone in the lower limb. Case report and Ki 67 immuno-histochemistry study. Virchows Arch 445:79–82

    PubMed  Google Scholar 

  18. Kandel R, Li SQ, Bell R et al (2006) Cyclin D1 and p21 is elevated in the giant cells of giant cell tumors. J Orthop Res 24(3):428–37

    Article  CAS  PubMed  Google Scholar 

  19. Matsubayashi S, Nakashima M, Kumagai K et al (2009) Immunohistochemical analyses of beta-catenin and cyclin D1 expression in giant cell tumor of bone (GCTB): a possible role of Wnt pathway in GCTB tumorigenesis. Pathol Res Pract 205(9):626–33

    Article  PubMed  Google Scholar 

  20. Okubo T, Saito T, Mitomi H et al (2013) p53 mutations may be involved in malignant transformation of giant cell tumor of bone through interaction with GPX1. Virchows Arch 463(1):67–77

    Article  CAS  PubMed  Google Scholar 

  21. Chakarun CJ, Forrester DM, Gottsegen CJ, Patel DB, White EA, Matcuk GR Jr (2013) Giant cell tumor of bone: review, mimics, and new developments in treatment. Radiographics 33:197–211

    Article  PubMed  Google Scholar 

  22. Popovic KS, Lukic S, Popovic P (2014) Pretreatment perfusion CT and CT volumetry in squamous cell carcinoma of the head and neck region. J BUON 19(4):937–43

    PubMed  Google Scholar 

  23. Cowan RW, Singh G (2013) Giant cell tumor of bone: a basic science perspective. Bone 52:238–246

    Article  PubMed  Google Scholar 

  24. Scully SP, Mott MP, Temple HT, O’Keefe RJ, O’Donnell RJ, Mankin HJ (1994) Late recurrence of giant-cell tumor of bone. A report of four cases. J Bone Joint Surg Am 76:1231–1233

    CAS  PubMed  Google Scholar 

  25. de Souza PE, Paim JF, Carvalhais JN, Gomez RS (1999) Immunohistochemical expression of p53, MDM2, Ki-67 and PCNA in central giant cell granuloma and giant cell tumor. J Oral Pathol Med 28(2):54–58

    Article  PubMed  Google Scholar 

  26. Prosser GH, Baloch KG, Tillman RM, Carter SR, Grimer RJ (2005) Does curettage without adjuvant therapy provide low recurrence rates in giant-cell tumors of bone. Clin Orthop Relat Res 435:211–218

    Article  Google Scholar 

  27. Wang HC, Chien SH, Lin GT (2005) Management of grade III giant cell tumors of bones. J Surg Oncol 92:46–51

    Article  PubMed  Google Scholar 

  28. Wadayama B, Toguchida J, Yamaguchi T, Sasaki MS, Yamamuro T (1993) p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas. Br J Cancer 68(6):1134–1139

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Levine AJ, Perry ME, Chang A et al (1994) The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 69(3):409–416

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Toguchida J, Yamaguchi T, Ritchie B et al (1992) Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res 52(22):6194–6199

    CAS  PubMed  Google Scholar 

  31. Wang H, Wan N, Hu Y (2012) Giant cell tumour of bone: a new evaluating system is necessary. Int Orthop 36(12):2521–7

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Orthopedic Surgery “Banjica”, School of Medicine, University of Belgrade, M. Avramovica St. 28, 11000, Belgrade, Serbia

    Nenad Lujic & Vladan Stevanovic

  2. Institute for Pathology, Medical Faculty, School of Medicine, University Belgrade, Dr Subotica 1, 11000, Belgrade, Serbia

    Jelena Sopta & Relja Kovacevic

  3. Institute of Nuclear Sciences “Vinča”, University of Belgrade, Mike Alasa 12-14, 11000, Belgrade, Serbia

    Radoslav Davidovic

Authors
  1. Nenad Lujic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jelena Sopta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Relja Kovacevic
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vladan Stevanovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Radoslav Davidovic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vladan Stevanovic.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Funding

This work was supported by the following Grants: III 45005, 175059, 173049 from the Ministry of Education, Science and Technological Development of the Republic of Serbia.

Ethical approval

All procedures followed were in accordance with the ethical standards and approved by the Ethics Committee, (Belgrade University; School of Medicine), the number of solution: 29/V-1 (11.10.2012.)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lujic, N., Sopta, J., Kovacevic, R. et al. Recurrence of giant cell tumour of bone: role of p53, cyclin D1, β-catenin and Ki67. International Orthopaedics (SICOT) 40, 2393–2399 (2016). https://doi.org/10.1007/s00264-016-3292-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00264-016-3292-2

Keywords

Search

Navigation